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ABSTRACT  
 
Administration of low-dose IL-2 alone or combined with rapamycin (RAPA) prevents 
hyperglycemia in NOD mice. Also, low-dose IL-2 cures recent onset type 1 diabetes (T1D) in 
NOD mice, partially by boosting pancreatic regulatory T cells (Treg cells). These approaches 
are currently being evaluated in humans. Our objective was to study the effect of higher IL-2 
doses (250,000-500,000 IU, daily) as well as low-dose IL-2 (25,000 IU, daily) and RAPA 
(1mg/kg, daily) (RAPA/IL-2) combination. We show that despite further boosting Treg cells, 
high doses of IL-2 rapidly precipitated T1D in pre-diabetic female and male mice and 
increased myeloid cells in the pancreas. Also, we observed that RAPA counteracted IL-2 
effects on Treg cells, failed to control IL-2-boosted NK cells and broke IL-2-induced tolerance 
in a reversible way. Notably, RAPA/IL-2 combination failure to cure T1D was associated to 
an unexpected deleterious effect on glucose homeostasis at multiple levels, including β-cell 
division, glucose tolerance and liver glucose metabolism. Our data help understand the 
therapeutic limitations of IL-2 alone or RAPA/IL-2 combination and could lead to the design 
of improved therapies for T1D. 
 
 
INTRODUCTION  
 
In type 1 diabetes (T1D), the immune system destroys the pancreatic ß-cells(1). At clinical 
onset, around 30 % of ß-cells are still able to produce insulin(2), thus stopping autoimmune 
destruction at this stage is a promising approach(3). Along the same lines, there is a growing 
list of Phase I/II clinical trials based on immunomodulation that are currently being conducted 
in T1D patients(4). 
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NOD mice, which develop spontaneous T1D, represent an accepted model to test new 
therapies(5), the gold standard being that treatments that cure overt hyperglycemia in these 
mice may be most appropriate for translation into the clinic, as was the case for anti-CD3 
Abs(6) which have been tested in patients with promising results(7). In addition, results from 
our own group showing that low-dose IL-2 can prevent(8) and revert disease in NOD mice(9), 
have led to the translation of this strategy into clinical trials in T1D patients (clinicaltrials.gov, 
NCT01353833).  
We have shown that in NOD mice, administration of low-dose IL-2 for 5 days induced the 
remission of new onset T1D by specifically boosting regulatory T cells (Treg cells) in the 
pancreas without activating pathogenic effector T cells (Teff cells). However, remission was 
obtained in only 60 % of treated mice and half of them became diabetic again during the 
following months(9). Consequently, improving IL-2 therapy by optimizing dosing or 
combining IL-2 with other immunomodulatory drugs, such as rapamycin (RAPA), could be of 
great importance for the goal of translating this therapy to humans.  
RAPA has been used in clinical transplantation for many years(10) and it has been safely 
administered to T1D patients during islet transplantation(11-12). In mice, RAPA 
monotherapy can prevent T1D development(13), however, it is unable to induce disease 
reversal(14). Moreover, RAPA and IL-2 were found to be synergistic for prevention of 
diabetes in NOD mice(13). Consequently, we decided to test whether RAPA could synergize 
with short-term IL-2 therapy to reverse T1D and reinforce the development of long-term 
tolerance.  
In this work, we have further studied the mechanisms of action of IL-2 and RAPA alone or in 
combination in the NOD model of T1D.  
 
RESEARCH DESIGN AND METHODS  
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Mice 
NOD mice were bred in our animal facility under specific pathogen-free conditions in 
agreement with current European legislation. Protocols were approved by The Ethics 
Committee in Animal Experiment Charles Darwin, France (number Ce5/2012/021). 
 
IL-2 and RAPA treatment 
Mice were treated with daily i.p. injections of 25,000 IU, 250,000 IU or 500,000 IU of 
recombinant human IL-2 (Proleukin, Novartis, France) for the indicated time. RAPA 
(Rapamune, Wyeth-Lederl ) was administered at 1mg/kg, per os, a dose that has been 
previously reported not to be toxic to pancreatic islets(13-14) and to prevent T1D onset in 
NOD mice(13). Glycosuria was measured using colorimetric strips (Multistix, Bayer) and 
blood glucose levels were quantified by a glucometer (Optium Xceed, Abbott).  
 
Spleen, LN and tissue-infiltrating lymphocytes preparation 
Spleen and LNs (axillary and brachial) and pancreatic lymph nodes (DLN) were isolated and 
dissociated in PBS-3% FCS. For pancreas-infiltrating lymphocytes preparation, whole 
pancreas was digested with collagenase/DNase solution and submitted to Percoll density 
gradient as described(15-16). 
 
Antibodies and flow cytometry analysis 
Anti-CD3, anti-CD4, anti-CD8, anti-CD45.1, anti-ICOS, anti-B220, anti-GITR, anti-Ly6C, 
anti-Ly6G, anti-CD11b, anti-CD11c, anti-CD19, anti-Gr1, anti-IFN-γ, anti-Ki67, anti-pStat5 
(pY694) and streptavidin-labeled with phycoerythrin, allophycocyanin , PerCP, PercP-Cy5.5, 
V500, APC-H7, PE-Cy7, Alexa Fluor-700, Alexa-647 or biotin, were from BD Biosciences. 
Anti-CD25, anti-CTLA-4, anti-NKp46 and anti-F4/80 labeled with FITC, PE-Cy7, APC or 
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eFluor 450 were from eBiosciences. The eFluor 450-anti-Foxp3 staining was performed using 
the eBioscience kit. For intracellular cytokine staining, cells were re-stimulated with 1µg/ml 
PMA/0.5µg/ml Ionomycin (Sigma) for 3 h, in the presence of GolgiPlug (1µl/ml) (BD 
Biosciences). For phospho-STAT-5 staining, DLNs were dissociated, immediately fixed in 
PBS 1.5% formaldehyde and permeabilized in MeOH., Cells were stained in PBS 0.2% BSA 
medium containing anti-CD4, anti-CD25, anti-Foxp3 and anti-pSTAT5 mAbs. PE-conjugated 
NRP-V7/H-2
K
 tetramer containing NRP-V7 peptide (KYNKANVFL) and control PE-
conjugated TUM/H-2
 K, 
tetramer containing TUM peptide (KYQAVTTTL) were kindly 
provided by Pere Santamaria. Cells were stained in RPMI 2% medium containing NRP-V7/H-
2K or TUM/H-2K at room temperature for 2 h, washed and further stained with anti-CD8 and 
anti-CD4 antibodies. Cells were acquired on a LSR II (BD Biosciences) and analyzed with 
FlowJo (Tree Star) software. 
 
Histology 
Pancreas were fixed in 10% formalin, embedded in paraffin and cut in 2µm thick sections and 
stained with hematoxylin/eosin. Insulitis scoring was evaluated microscopically.  
For immuno-histology, pancreas were embedded in optimal cutting temperature (OCT) 
medium, snap-frozen in liquid nitrogen and stored at -80°C until use. Eight µm thick-sections 
were blocked with PBS 2% BSA, stained with anti-mouse insulin (Sigma) followed by 
biotinylated anti-mouse IgG1 (Abcam) and APC-labeled streptavidin, PE-labeled anti-CD45.1 
and FITC-labeled anti-Ki67 (BD Biosciences) and counterstained with Hoechst (Dako). 
Proliferating β-cells were defined as Ki67
+
 Insulin
+
 CD45.1
-
 and manually counted. For 
CD11b staining, FITC-anti-CD11b (BD Biosciences) was used. Images were acquired on a 
Leica epifluorescence microscope and analyzed with Metavue Software. 
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Determination of wet weight of organs 
Organs were weighed before and after lyophilization overnight at 58°C under vacuum and 
wet weight was calculated by subtracting initial weight from weight after lyophilization, as 
described(17). 
 
Glucose/insulin tolerance test (IPGTT/ITT) 
Twelve week-old non-diabetic NOD female mice were treated for 5 days with PBS, 25,000 
IU IL-2, IL-2, RAPA or 25,000 IU IL-2 plus RAPA and the last administration was 
performed 2h before the beginning of the IPGTT/ITT. For IPGTTs, a single dose of 2g 
glucose/kg was injected i.p. after 16 h overnight fast. For ITTs, a single dose of 0.75 IU 
insulin/kg (Humulin R, Lilly) was injected i.p. after 4h fasting and blood glucose levels were 
determined.  
 
Sample generation and DNA microarray hybridization and analysis 
Twelve week-old non diabetic NOD female mice were treated for 5d with PBS, 25,000 IU 
IL-2, RAPA or IL-2 plus RAPA. Mice were fasted for 16h before the injection of a glucose 
bolus (2 g/kg) 2h after the last administration of IL-2 and/or RAPA. Four hours after the 
glucose challenge, mice were euthanized, perfused with 0.9% NaCl and liver was collected. 
Tissue was processed (TissueLyser II, Qiagen) and RNA was generated (RNeasy Mini kit, 
Qiagen). RNA quality was verified in an Agilent Bioanalyzer and measured with a 
Nanodrop 1000 (Thermo Scientific). 
Microarray experiments were performed on Illumina MouseWG-6 BeadChip. Data were 
Quantile normalized using BeadStudio software. The working lists were created by filtering 
probes with detection p values <0.05 for all the chips and discarding overlapping probes. 
Each data set was derived from 3 biologically
 
independent replicate samples. Independent 
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samples were compared by computing fold ratios and filtered at a 1.5-fold threshold for 
Venn Diagrams and 1.2-fold threshold for pathway analysis. For pathway analysis, 
GenBank accession numbers were mapped to the Ingenuity database (IPA, 
http://www.ingenuity.com) to retrieve relevant biological processes. 
Microarray data accession number: E-MEXP-3789 
 
Statistical analyses 
Statistical significances were calculated using two-tailed unpaired Student t-test with 95% 
confidence intervals. When sample distribution was not normal (as determined by a 
D’Agostino and Pearson omnibus normality test), Mann-Whitney-Wilcoxon non-parametric 
test was used. Survival proportions were calculated using the Kaplan-Meier method and 
statistical significances were calculated using the Gehan-Breslow-Wilcoxon test. All 
statistical significances were calculated with GraphPad Prism v5.0 software. 
 
 
RESULTS 
 
High doses of IL-2 are toxic and can precipitate T1D development: 
We have previously shown that 5 doses of 25,000 IU IL-2 could revert new-onset T1D in 
NOD mice in part by specifically boosting pancreatic Treg cells(9). However, not all treated 
mice were cured and in some of them the beneficial effects were transient. We reasoned that 
increasing the dose of IL-2 administered may further increase the frequency of Treg cells and 
thus improve the treatment efficacy. 
We first tested the capacity of higher IL-2 doses to prevent T1D development. We found that 
daily treatment of NOD mice with 250,000 or 500,000 IU IL-2 (i.e., doses ten- or twenty-fold 
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higher than the dose shown to prevent T1D(8) could be lethally toxic in a dose-dependent 
manner in 5 week-old mice (Figure 1A, upper panel). In pre-diabetic mice at 12-14 weeks of 
age, this treatment was less toxic but it dramatically precipitated the onset of diabetes after 
only a few daily injections and in a dose-dependent manner (Figure 1A, middle and bottom 
panels). At the 250,000 IU IL-2 dose, females were significantly more sensitive than males to 
IL-2-induced acceleration of diabetes (Figure 1A, bottom panel).  
IL-2 toxicity is mainly associated with vascular leak syndrome (VLS), which can lead to 
hypotension, pulmonary edema, liver cell damage, and even death(17). We thus measured 
organ edema after 5 days of high-dose IL-2 administration (Figure 1B). Unlike C57BL/6 
mice(18), higher cumulative doses of IL-2 were necessary before VLS became evident in 
NOD mice. Moreover, we observed gender-dependent differences, with lung edema being 
most prominent in males and liver edema in females. Brain edema did not develop in either 
group. Additionally, we measured islet infiltration in these mice and observed that 5 days of 
high-dose IL-2 administration induced a mild increase of invasive insulitis in males (Figure 
1C).  
The rapid onset of T1D, observed as early as after only 3 days of treatment, was not due to an 
immediate detrimental effect of IL-2 on glucose homeostasis, as administration of 250,000 IU 
IL-2 did not induce any apparent alteration in glucose metabolism after a glucose bolus 
administration 2 hours after the IL-2 injection (Figure 1D).  
Low-dose IL-2-induced T1D remission was associated with Treg cell activation only in the 
pancreas, whereas Teff, CD8
+
 and NK cells were not noticeably affected by this treatment(9). 
On the contrary, high-dose IL-2 induced systemic effects, including increased cell numbers in 
secondary lymphoid organs, most significantly in the pancreas draining lymph nodes (DLN) 
(Figure 2A). In the DLN (Figure 2B), non-draining lymph nodes (LNs) and spleen (not 
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shown), significantly higher proportions of NK cells along with lower frequencies of total 
CD4
+
 T cells but with increased Treg cell proportions, were observed. 
In the islets, high-dose IL-2 effects were more pronounced (Figure 2B). Notably, total CD4
+ 
T cells were unchanged but an almost double frequency of Treg cells were seen following IL-2 
treatment. Also NK, CD11c
+
 and CD11b
+
 cells increased after IL-2 administration. 
Interestingly, in almost all analyzed organs, Treg, Teff, CD8
+
, NK, B and CD11b
+
 cells 
increased their division after high-dose IL-2 administration, as assessed by quantification of 
Ki67 expression (Figure 2C). In particular, more than 80 % of NK and CD11b
+
 had cycled in 
the pancreas. Indeed, by immuno-histology analysis these highly proliferative CD11b
+ 
cells 
were found interspersed around the islets and surrounding blood vessels (Figure 3A). Further 
phenotypic analysis indicated that two subpopulations among CD11b
+
 cells increased during 
IL-2 treatment: CD11b
+
 Ly6C
+
 F4/80
+
 cells, likely representing tissue macrophages, and 
CD11b
+ 
Ly6G
+
 cells, likely representing neutrophils(19) (Figure 3B).  
Detailed analysis of the effects of IL-2 on Treg cells indicated that the cytokine increased the 
expression of Foxp3 and CD25 in a dose-dependent way, suggesting an enhancement of Treg 
cell fitness (Figure 4A). Similarly, even though the frequency of Teff cells was diminished, 
their activation was potentiated by IL-2 administration, as indicated by the dose-dependent 
increase in the fraction of CD25
+ 
Teff and CD8
+
 T cells, mainly observed in the islets (Figure 
4B). Moreover, Teff, CD8
+
 and NK cells showed increased IFN-γ production (Figure 4C) 
during treatment with high-dose IL-2. Additionally, among the expanded CD8
+
 T cell 
population, we observed a significant increase in the frequencies of NRPV7
+
 IGRP-specific 
autoreactive CD8 T cells(20) in the blood and in the islets of the treated mice (Figure 4D). 
 
RAPA partially counteracts the activation of pancreatic Treg cells induced by low-dose IL-2 
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The immunomodulatory effects of RAPA have been attributed to its capacity to preferentially 
affect activated Teff cells, while Treg cells are less susceptible to its action(21). Consequently, 
we hypothesized that the beneficial effect of low-dose IL-2 on Treg cells could synergize with 
the concomitant elimination of pathogenic Teff cells by RAPA after administration of a 
RAPA/low-dose IL-2 combination. 
We analyzed the effects of combined treatment on lymphoid cells in pre-diabetic NOD 
females, in which insulitis is already important. Administration for 5 days of RAPA alone, 
low-dose IL-2 alone, or both drugs combined did not induce major changes in absolute 
numbers and frequencies of T cells in the spleen, LNs and DLN (data not show). In the 
pancreas, low-dose IL-2 alone did not modify the frequency of total CD8
+
 or CD4
+
 T cells 
(data not shown). However, it modified the Treg/Teff balance by increasing the percentage of 
Treg cells (Figure 5A), which was associated with increased cell division (Figure 5B) and 
increased expression of Foxp3, CD25, glucocorticoid-induced tumor necrosis factor receptor 
(GITR), ICOS and cytotoxic-T lymphocyte antigen 4 (CTLA-4) (Figure 5C). A similar 
tendency was observed when low-dose IL-2 was combined with RAPA. Notably, the effect of 
IL-2 on Treg cell numbers or activation was significantly less pronounced in the presence of 
RAPA (Figure 5A-C).  
Finally, we examined the effects of treatment on NK cells in the pancreas and observed that 
their proportion doubled after 5 days of treatment with low-dose IL-2 alone, with the 
percentage of proliferating cells increasing from low basal levels up to around 60% after 
treatment (Figure 5D-E). Addition of RAPA to IL-2 treatment did not modify the effect of 
IL-2 on NK cells.  
We discarded that the partial counteraction of IL-2 effects on Treg cells by RAPA was due to 
interference of the JAK/STAT pathway, as IL-2-mediated STAT5 phosphorylation was not 
modified by the administration of RAPA in vivo (Figure 6). 
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RAPA inhibits the ability of low-dose IL-2 to revert T1D 
To test whether RAPA could reinforce the development of long-term tolerance when 
combined with IL-2, we treated new onset T1D NOD mice with 25,000 IU (low-dose) IL-2 
with or without RAPA. In agreement with our previously reported results (9), low-dose IL-2 
treatment induced diabetes remission in 57 % of the mice. However, none of the 12 mice that 
received the combined treatment was cured (Figure 7A). We assessed the effects of treatment 
on pancreatic T cells from these mice: RAPA/IL-2 combination did not modify the percentage 
of total CD8
+
 or CD4
+
 T cells (not shown) but it significantly increased the frequency of Treg 
cells (Figure 7B). Interestingly, RAPA hampered the IL-2-induced reduction in IFN-γ 
production by CD8
+
 T cells infiltrating the pancreas (Figure 7C), which we had previously 
shown to be associated with T1D reversal(9). These results may partially explain why RAPA 
inhibits the ability of IL-2 to revert disease. 
 
To determine whether RAPA had any effect in mice that had reverted from new-onset T1D 
after low-dose IL-2 therapy, we administered RAPA to NOD mice 10 days after IL-2-induced 
disease remission. Surprisingly, RAPA precipitated hyperglycemia in all previously cured 
mice (Figure 7D). Of note, in 2 out of 8 treated mice, RAPA induced irreversible 
hyperglycemia, but in the other 6 IL-2-treated mice, the hyperglycemia triggered by RAPA 
was transient. Indeed, after RAPA withdrawal and without further addition of IL-2, mice 
spontaneously became normoglycemic again until RAPA treatment was resumed, at which 
point mice reversed to diabetes. In some of these mice, the transient occurrence of diabetes 
upon adding and removing RAPA could be repeated at least three times, indicating that 
RAPA can reversibly inhibit the tolerogenic effect of IL-2. We analyzed the temporal effect 
of RAPA on the pancreatic infiltrate. Intriguingly, Treg cell levels in the pancreas were 
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significantly lower in mice cured from diabetes with IL-2 but which had become diabetic 
again after RAPA treatment as compared to mice that did not receive RAPA and a significant 
parallel increase in these cells was observed in the DLN (Figure 7E-F). Treg cells returned to 
initial levels after RAPA withdrawal and restoration of euglycemia, suggesting that under 
RAPA treatment the migration pattern of CD4
+
 T cells may be altered.  
 
The combination IL-2 plus RAPA impairs glucose tolerance: 
The rapid reversibility of the effect of RAPA on diabetes led us to evaluate whether RAPA 
was affecting glucose homeostasis. We measured fasting blood glucose levels and performed 
glucose tolerance tests in pre-diabetic NOD mice previously treated with IL-2, RAPA or both 
combined. Low-dose IL-2 treatment did not modify glucose homeostasis (Figure 8A-B), in 
agreement with results obtained with high doses of IL-2 (Figure 1D). However, RAPA/IL-2 
combination induced elevated fasting blood glucose levels (Figure 8A) and also, RAPA and 
RAPA/IL-2-treated mice displayed highly impaired glucose tolerance (Figure 8B). 
Mechanistically, RAPA-induced glucose intolerance could be due to direct β-cell toxicity or 
to peripheral insulin resistance; we thus monitored β-cell division and performed insulin 
tolerance tests (Figure 8C-D). Even if neither RAPA nor RAPA/IL-2 treatments visibly 
modified the response to an exogenous insulin boost, RAPA/IL-2 administration significantly 
reduced basal β-cell proliferation in vivo. 
Finally, to better understand how RAPA alone or combined with IL-2 interfered with glucose 
homeostasis, we studied by microarray analysis the liver response to a glucose challenge. As 
depicted (Figure 8E and Supplementary Figure 1), the liver transcriptome signature was 
highly modified by IL-2 alone (81 genes) or combined with RAPA (40 genes), whereas fewer 
genes were affected by RAPA alone (16 genes). To retrieve relevant biological processes 
associated to the different treatments, we analyzed the canonical pathways that were most 
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significant to our data sets (Supplementary Table 1). RAPA- and IL-2-modified transcripts 
were associated mainly with metabolic and immune pathways, respectively. Interestingly, 
RAPA/IL-2 combination modified other pathways than each drug alone, most of them 
involving metabolic functions. These data further document the complex effects of these 
drugs beyond immune-modulation and may partially explain the associated detrimental 
effects on glucose homeostasis. 
 
 
DISCUSSION 
 
Low-dose IL-2 administration represents one promising approach(9) (clinicaltrials.gov, 
NCT01353833) among the novel immunotherapies being evaluated in T1D patients(4). We 
reasoned that we could enhance the efficiency with which IL-2 induces a tolerogenic state in 
NOD mice(9) by increasing its dose. However, higher IL-2 doses dramatically accelerated 
disease onset and demonstrated a toxicity that could even be lethal. Interestingly, female NOD 
mice were significantly more susceptible than males to diabetes induction, correlating with 
the higher incidence of spontaneous T1D in females mice (70 %) compared to males 
(30%)(23). Additionally, high-dose IL-2-associated organ edema and insulitis appeared 
dissimilar in males and females, suggesting that IL-2-related side effects may be sex-
dependent in the NOD mice.  
T1D appeared in some of the mice treated with high-dose IL-2 despite substantial local and 
systemic increase in the frequency and activation of Treg cells. Disease occurrence could be 
explained by the concurrent activation of Teff, NK, B, and CD8
+ 
T cells, all of which have 
been implicated in T1D development(3; 24). Of note, among CD8
+
 T cells, islet-specific ones 
were enriched in the pancreas, potentially contributing to the destruction of the β-cells. 
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Remarkably, high doses of IL-2 induced a previously unreported yet striking increase in 
CD11b
+
 myeloid cells in the pancreas. Historically, macrophages have been regarded as 
mediators of insulitis(25). However recently, myeloid cells have been associated with T1D 
resistance and prevention in NOD mice(26-28). The role of different myeloid subpopulations 
in disease pathogenesis is nevertheless still being largely unknown.   
Overall, higher doses of IL-2 resulted in a shift from immune tolerance to overt destructive 
autoimmunity. In the context of human therapy, these results highlight the need to perform 
thorough immunomonitoring of the broad effects of IL-2 so as to determine the dose that 
would uniquely act on Treg cells or other regulatory populations. 
 
The potent immunosuppressive properties of RAPA are associated with its capacity to block 
cell cycle progression and induce T cell anergy and depletion(29), thus impacting on T-cell 
differentiation and function. In our model, RAPA specifically dampened IL-2 effect on 
pancreatic Treg cells. Notably, diabetic animals receiving IL-2/RAPA combination showed 
higher frequencies of pancreatic Treg cells compared to treatment with IL-2 alone, which 
nevertheless were associated with inefficient control of IFN-γ production by infiltrating T 
cells. These Treg cells could originate from the expansion of pre-existing natural Treg cells or 
from the generation of induced Treg cells from Teff cells, probably favored by the pro-
inflammatory environment in the islets(30).  
We could not attribute the deleterious impact of IL-2/RAPA combination on Treg cell function 
to interference of RAPA on IL-2-mediated activation of STAT-5. However, although Treg 
cells are less dependent for survival on the AKT/mTOR pathway than Teff cells(33), it is 
possible that RAPA inhibition of this pathway may still affect IL-2 action on Treg cells(34-35). 
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NK cells have been described as having no role(36) or a pathogenic role in NOD T1D(37). In 
humans, they have been seen as either potentially harmful(38-39) or regulatory(40-41). Thus, 
their role in T1D progression is still debated. Human NK cells have been found to be 
significantly increased upon IL-2 administration(42-43), notably in T1D patients(35). In our 
model, after IL-2 administration NK cells rapidly expanded in the pancreas following IL-2 
administration. Of note, the effect of IL-2 on NK cells was not affected by the addition of 
RAPA, raising the hypothesis that, in comparison to IL-2 monotherapy, RAPA/IL-2 
combination may negatively impact on pancreatic Treg cells, while failing to control IL-2-
boosted NK cells. This is reminiscent of the previous observation that punctual ablation of 
Treg cells in NOD-BDC2.5 TCR-transgenic mice resulted in a fulminant form of diabetes 
characterized by an initial burst in NK cell function which led to IFN-γ−dependent activation 
of pathogenic T cell populations(44).  
Although our data suggest that the deleterious effects of RAPA in IL-2-treated NOD mice 
may be related to its action on Treg cell function or trafficking, we also found that a short 
course of RAPA and IL-2 at low doses significantly impaired glucose homeostasis. There 
have been some reports of renal transplant patients chronically treated with RAPA becoming 
at risk of developing new-onset diabetes, associated with abnormal glucose and lipid 
homeostasis and with reduced insulin sensitivity(45). Furthermore, in rodents, chronic RAPA 
treatment severely impairs glucose tolerance, affecting hepatic gluconeogenesis(46-47), 
adipocytes lipid uptake(46), skeletal muscle insulin sensitivity(48) and β-cell 
homeostasis(46). However, RAPA alone prevents T1D development in NOD mice (13; 49) 
and has been reported to improve Treg cell suppressive function in T1D patients(12). Here, we 
demonstrate that RAPA administration even for a short period and at doses 2-5-times lower 
than those reported in the literature(46-47), impaired glucose tolerance, as previously 
suggested(14), and modified liver glucose metabolism in the NOD model. Moreover, when 
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combined with IL-2, the negative effects on glucose metabolism were broadened; also 
inducing elevated basal blood glucose levels and impairing β-cell proliferation. Interestingly, 
our results showing that RAPA restored diabetes in NOD mice which had been previously 
cured of new onset disease by IL-2 treatment evoke RAPA effects counteracting anti-CD3 
treatment in NOD mice(14).  
Recently, a clinical trial testing RAPA/IL-2 combined therapy in new onset T1D patients was 
halted due to a transient drop in C-peptide levels in all patients, despite effective Treg cell 
induction(35). Our results showing that RAPA breaks IL-2-induced tolerance and that, in 
combination with IL-2 it induces glucose intolerance; help understand the inefficacy and 
deleterious consequences of the combined treatment in T1D. However, RAPA/IL-2 
combination can be efficient at boosting Treg cells and inducing tolerance in graft-versus-host 
disease(42; 50). The latter results, which were observed in hosts devoid of the metabolic 
alterations associated with T1D, demonstrate the different potential outcomes of the combined 
treatment depending on the underlying pathology. And even when referring to T1D, it is 
surprising to observe that RAPA and IL-2 combination can have a completely different 
outcome in preventive or curative schedules in the NOD mice(13). Probably, in pre-diabetic 
mice, the effects of RAPA are not strong enough to cause hyperglycemia because, at odds 
with already diabetic mice, there are enough healthy islets to compensate for the negative 
effects of RAPA, at least for a short-term treatment. 
Our results, together with the accumulated experience in the use of IL-2 and RAPA in the 
context of T1D prevention or reversal (see recapitulation in Supplementary Table 2), help 
define the limitations of the application of these drugs in T1D and may contribute to the 
design of improved IL-2-based therapy. 
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FIGURE LEGENDS 
 
Figure 1. Administration of high doses of IL-2 to NOD mice: toxicity and diabetes 
development. (A) Male and female NOD mice of 5 weeks of age (upper panel) or 12-14 
weeks of age (middle and bottom panels) were injected daily with PBS (black circles = 
females; white circles = males), 250,000 IU IL-2 (black squares = females; white squares = 
males) or 500,000 IU IL-2 (black triangles = females; white triangles = males) during 20 
days. Shown are Kaplan-Meier survival curves of treated mice (upper and middle panels) and 
percentage of diabetes free mice; * P < 0.05 (Gehan-Breslow-Wilcoxon test) (bottom panel). 
(B-C) Male and female NOD mice of 12-14 weeks of age were injected for 5 days with PBS 
(black circles = females; white circles = males,) or 250,000 IU IL-2 (black squares = females; 
white squares = males) and analyzed 2 h after the last injection. (B) Wet weight of lung (left 
panel), liver (middle panel) and CNS (right panel) were determined. Symbols represent 
individual mice and horizontal lines represent the median. ** P < 0.01 (unpaired, two-tailed 
Student’s t test). (C) Histological quantification of islet infiltration by immune cells in female 
and male NOD mice. Shown are percentages of islets with no infiltration (0), peri-insulitis (1), 
moderate insulitis with less than 50% islet area infiltrated by immune cells (2), and severe 
insulitis with more than 50% islets area infiltrated by immune cells (3). Pictures show 
representative islets corresponding to the insulitis score used for analysis. (D) Pre-diabetic 
female NOD mice of 12-16 weeks of age were fasted for 4 h and injected with PBS or 
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250,000 IU IL-2 followed by a glucose bolus 2 h later. Results are presented as blood glucose 
levels during the 4 h follow-up (left panel) and as area under the blood glucose curve (AUC) 
during the follow-up period (right panel), symbols represent individual mice and horizontal 
lines represent the median. Data cumulate 2 (A, top panel) to 5 (A, middle and bottom panels) 
independent experiments or are representative of 1 (B,C) to 3 (D) independent experiments.  
 
Figure 2. Administration of high doses of IL-2 to NOD mice: effects on immune cells. 
Pre-diabetic female NOD mice of 12-14 weeks of age were treated daily with PBS, 250,000 
or 500,000 IU IL-2 during 5 days and analyzed 2 h after the last injection. (A) Absolute cell 
numbers in DLN, non-draining LNs (LNs) and spleen. (B) Percentage of total CD4
+
, CD8
+
, 
NKp46
+
 CD3
-
 (NK), B, CD11c
+
 and myeloid CD11b
+
 cells in DLN (upper panel) or in 
pancreas (lower panel). Right panels indicate the percentage of Treg cells among total CD4
+
 T 
cells. (C) Representative histograms of Ki67 expression (left panels) and percentages of Ki67
+
 
cells among indicated populations (right panels) in the DLN and pancreas. Similar results 
were obtained in male NOD mice (not shown). Data cumulate 3 to 5 independent experiments 
with 4 to 14 mice per group. Symbols represent individual mice and horizontal lines represent 
the median. * P < 0.05; ** P < 0.01; *** P < 0.001 (unpaired, two-tailed Student’s t test). 
 
Figure 3. Administration of high doses of IL-2 to NOD mice: effects on myeloid cells. 
Mice were treated as in Figure 2. (A) Representative immunofluorescence of cryosections 
from the pancreas of mice treated with PBS (top) or 250,000 IU IL-2 (bottom), stained with 
anti-CD11b Abs (green) and Hoechst (blue) (magnification x200). Dashed line indicates 
blood vessels. (B) Myeloid cell gating strategy: islet infiltrating cells were pre-gated as 
CD45
+
 NKp46
-
 and expression of CD11b versus Ly6C was used to define gates R1 and R2 as 
shown. Cells in these gates were further analyzed for the expression of F4/80 and Ly6G. Cells 
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in gate R1 were mostly F4/80
-
 and Ly6G
+
, probably representing neutrophils and cells in gate 
R2 were mostly F4/80
+
 and Ly6G
-
, probably representing tissue macrophages. (C) 
Percentages of cells in gate R1 (upper panel) and R2 (lower panel) in islets, DLN, LNs and 
spleen of mice in indicated treatment groups. Data cumulate 2 independent experiments with 
2 to 5 mice per condition, except for panel A, which is from one experiment with 3 mice per 
group. Symbols represent individual mice and horizontal lines represent the median. * P < 
0.05; ** P < 0.01; ***P < 0.001 (unpaired, two-tailed Student’s t test). 
 
Figure 4. Administration of high doses of IL-2 to NOD mice: effects on cell activation 
and cytokine production. Mice were treated as in Figure 2 and DLN and pancreas 
infiltrating cells were analyzed by flow cytometry. (A) Left panels: representative contour 
plots of Foxp3 and CD25 expression in CD4
+
 T cells in indicated groups. Right panels: 
relative MFI (mean fluorescence intensity) of Foxp3 and CD25 in Treg cells expressed as 
relative percentage of the MFI value in non-draining LN of PBS treated mice, which was 
assigned an arbitrary value of 100%. (B) Percentages of CD25
+
 cells among CD4
+
 Foxp3
-
 
(Teff cells) (top) and CD8
+
 T cells (bottom). (C) Representative contour plots of IFN-γ staining 
(left panels) and percentage of IFN-γ secreting cells (right panels) among islet-infiltrating 
CD4
+
 Foxp3
-
 (top panels), CD8
+
 (middle panels) and NK cells (bottom panels) quantified 
after ex vivo stimulation with PMA-ionomycin. Data are cumulative of 2 to 3 independent 
experiments with 4 to 9 mice per group. * P < 0.05; ** P < 0.01; *** P < 0.001 (unpaired, 
two-tailed Student’s t test). (D) Upper panels: representative histograms of control TUM and 
NRP-V7 tretramer expression on CD8
+
 T cells from blood and islets. Lower panels: 
percentage of NRP-V7
+
 CD8
+
 T cells among total CD8
+
 T cells in blood (left) and in the 
pancreatic islets (left). Data are from one experiment, symbols represent individual mice and 
horizontal lines represent the median. * P < 0.05; (unpaired, two-tailed Mann-Whitney test). 
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Figure 5. Effects of combined low-dose IL-2 and RAPA on immune cells. Pre-diabetic 
female NOD mice of 12-14 weeks of age were treated daily with PBS (n=10), 25,000 IU IL-2 
(n=8), RAPA (1 mg/kg) (n=12) or both (n=10) during 5 days and pancreas-infiltrating cells 
were collected and stained for flow cytometry analysis 2 h after the last treatment. (A) 
Percentages of Treg cells among CD4
+
 T cells. (B) Representative overlay histograms of Ki67 
expression (left panel) and percentages of Ki67
+
 Treg cells (right panel) in indicated groups. 
(C) Representative overlay histograms of Foxp3, CD25, GITR, ICOS and CTLA-4 expression 
in Treg cells (upper panels) and respective MFI (lower panels) expressed as relative percentage 
of the MFI value in non draining LN of untreated mice which was assigned an arbitrary value 
of 100%. (D) Percentages of NKp46
+
 CD3
-
 NK cells among pancreas infiltrating cells. (D) 
Representative overlay histograms of Ki67 expression (left panel) and percentages of Ki67
+
 
NK cells (right panel). Data are cumulative of 4 independent experiments, symbols represent 
individual mice, and horizontal lines represent the median. * P < 0.05; ** P < 0.01; *** P < 
0.001 (unpaired, two-tailed Student’s t test). 
 
Figure 6. IL-2 and RAPA effects on STAT5 phosphorylation. Pre-diabetic female NOD 
mice of 12-16 weeks of age were injected with PBS (PBS), 1 mg/kg RAPA 16 and 2 h before 
analysis, 250,000 IU IL-2 (IL-2) 2 h before the analysis or the combined treatment (IL-2 + 
RAPA). Phosphorylation of STAT5 on Treg cells (CD4
+
 Foxp3
+
 T cells) and Teff cells (CD4
+ 
Foxp3
-
 T cells) was determined by flow cytometry. Shown are: the gating strategy to define 
the percentage of p-STAT5
+
 Treg and Teff cells (upper graph) and the percentage of p-
STAT5
+
 Treg cells (bottom left panel) or Teff cells (bottom right panel) in the DLN. Data are 
cumulative of 3 independent experiments, symbols represent individual mice and horizontal 
lines represent the median. *** P < 0.001 (unpaired, two-tailed Student’s t test). 
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Figure 7: RAPA abrogates IL-2-induced tolerance. New-onset diabetic NOD mice were 
treated daily for 5 d with PBS or 25,000 IU IL-2, or for 10 d with 1mg/kg RAPA along with 
25,000 IU IL-2. (A) Percentage of T1D remission. (B-C) Islet infiltrating cells were analyzed 
2h after the last injection. (B) Percentage of Treg cells among CD4
+
 T cells. (C) Percentage of 
IFN-γ
+
 cells among CD8
+
 T cells quantified after ex vivo re-stimulation with PMA-
ionomycin. Symbols represent individual mice and horizontal bars are mean values. * P < 
0.05; ** P < 0.01; *** P < 0.001 (unpaired, two-tailed Student’s t test). (D) New-onset 
diabetic NOD mice were cured by low-dose IL-2 and were treated with RAPA (1mg/kg) 10 
days after remission until the appearance of hyperglycemia (for 4 and up to 8 days). Arrows 
indicate RAPA administration. For some mice in which blood glucose levels normalized after 
RAPA withdrawal, a subsequent RAPA treatment was initiated after 10 days of 
normoglycemia, and depending on the individual mice, this cycle could be repeated up to 3 
times. Response to treatment of 3 individual mice is shown. “Diabetic” indicates blood 
glucose levels above 250 mg/dl or positive glycosuria and “Non diabetic” indicates blood 
glucose levels below 250 mg/dl or negative glycosuria. (E-F) The percentage of CD4
+ 
Foxp3
+
 
T cells among CD4
+
 cells was analyzed by flow cytometry in the DLN and the islets of 
individual mice at different points during treatment. (E) Representative dot plots of Foxp3 and 
CD4 staining among CD4
+
 T cells. (F) Percentage of Treg cells among CD4
+
 T cells in the 
DLN (upper panel) and in the islets (lower panel). Symbols represent individual mice and 
horizontal lines represent the median. Cured= IL-2 cured mice (n=6); diabetic after RAPA= 
mice that became diabetic under RAPA treatment (n=5); reverted after RAPA withdrawal= 
mice that regained normal glucose homeostasis after RAPA withdrawal (n=3). * P < 0.05 
(unpaired, two-tailed Mann-Whitney test). 
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Figure 8. A short course of RAPA alone or combined with IL-2 induces glucose 
intolerance. Pre-diabetic female NOD mice were treated for 5 days with PBS, 25,000 IU IL-
2, 1 mg/kg RAPA, or IL-2 and RAPA combined. (A-B, E) On day 5, an intra-peritoneal 
glucose tolerance test (IPGTT) was performed after an overnight fast or mice were euthanized 
4 h after the glucose bolus for transcriptome analysis of the liver. (A) Fasting blood glucose 
levels were determined before glucose injection. (B) Shown are blood glucose levels and area 
under the blood glucose curve (AUC) of the treated mice of the different groups (n=7-8 per 
group). Data are cumulative of 2 independent experiments with 7 mice per group. Symbols 
represent individual mice and horizontal lines represent the median. * P < 0.05; ** P < 0.01; 
*** P < 0.001 (unpaired, two-tailed Student’s t test). (D) Percentage of Ki67
+
 cells among 
total beta cells (insulin
+
 CD45.1
-
). Each column represents the mean ± SEM of all islets 
counted for all mice of the same group (n=3-4 per group). * P < 0.05 (Mann-Whitney test). 
(D) On day 5, an insulin tolerance test (ITT) was performed after a 4 h fast. Shown are blood 
glucose levels and area under the blood glucose curve (AUC) of the treated mice of the 
different groups (n=7 per group). Symbols represent individual mice and horizontal lines 
represent the median. (E) Venn diagram comparing differentially expressed genes in the liver 
after glucose challenge of mice in IL-2 vs. PBS, IL-2/RAPA vs. PBS and RAPA vs. PBS 
groups. The threshold for differential expression was defined as 1.5-fold changes in 
expression with overlapping probes discarded. Each number represents the number of genes 
in each subgroup: total number of genes (Total) and up-regulated (Up, or U) and down-
regulated (Down, or D) probes from reference PBS. Each data set was derived from 3 
biologically
 
independent replicate samples.  
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Figure 1. Administration of high doses of IL-2 to NOD mice: toxicity and diabetes development.  
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Figure 2. Administration of high doses of IL-2 to NOD mice: effects on immune cells.  
220x269mm (300 x 300 DPI)  
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Figure 3. Administration of high doses of IL-2 to NOD mice: effects on myeloid cells.  
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Figure 4. Administration of high doses of IL-2 to NOD mice: effects on cell activation and cytokine 
production.  
226x284mm (300 x 300 DPI)  
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Figure 5. Effects of combined low-dose IL-2 and RAPA on immune cells.  
158x139mm (300 x 300 DPI)  
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Figure 6. IL-2 and RAPA effects on STAT5 phosphorylation.  
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Figure 7: RAPA abrogates IL-2-induced tolerance.  
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Supplementary Figure 1. RAPA alone or combined with 
IL-2 impacts on liver glucose metabolism: microarray 
analysis. Heat maps show the genes from the comparison of 
IL-2 vs PBS, IL-2/RAPA vs PBS and RAPA vs PBS lists, 
filtered at 1.5-fold change as depicted in the Venn diagram. 
The intensity of green and red colors indicates the degree of 
down or up-regulation, respectively. 
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Supplementary Table 1. RAPA alone or combined with IL-2 impacts on liver glucose metabolism: pathway analysis. 
 
 
 
 
 
 Ingenuity Canonical Pathways 
 -log(p-
value) 
Ratio Molecules 
IL-2 ONLY 
Immune 
response 
Communication between Innate and Adaptive Immune Cells 3,26E00 7,53E-02 TLR2,IL1RN,TLR6,HLA-B,HLA-DRB1,CD86,HLA-F 
Complement System 1,75E00 9,09E-02 C8B,C1QA,C6 
IL-10 Signaling 1,52E00 5,56E-02 CCR5,BLVRA,IL1RN,CHUK 
IL-8 Signaling 2,33E00 4,69E-02 PLD4,VEGFA,RAC2,ARRB2,RHOG,CHUK,IQGAP1,FNBP1,EGFR 
Interferon Signaling 2,57E00 1,18E-01 OAS1,IFITM1,PSMB8,STAT1 
Lipid Antigen Presentation by CD1 1,37E00 9,09E-02 CALR,PDIA3 
NF-κB Signaling 1,63E00 4,12E-02 SIGIRR,TLR2,TGFBR2,IL1RN,TLR6,CHUK,EGFR 
Toll-like Receptor Signaling 2,59E00 8,77E-02 SIGIRR,TLR2,PPARA,TLR6,CHUK 
Metabolism 
Lipoate Biosynthesis and Incorporation II 1,46E00 5E-01 LIAS 
PXR/RXR Activation 1,63E00 6,25E-02 PPARA,SCD,ALDH1A1,NR1I2 
Sorbitol Degradation I 1,76E00 1E00 SORD 
Sucrose Degradation V (Mammalian) 2,23E00 2,86E-01 ALDOB,GALM 
Superpathway of Citrulline Metabolism 1,62E00 1,43E-01 ASL,ARG1 
RAPA ONLY Metabolism 
PI3K/AKT Signaling 1,83E00 2,96E-02 HSP90B1,NFKBIA,HSP90AB1,EIF4EBP1 
4-hydroxyproline Degradation I 1,81E00 5E-01 ALDH4A1 
Acetyl-CoA Biosynthesis I (Pyruvate Dehydrogenase Complex) 1,34E00 1,67E-01 DBT 
Arginine Degradation I (Arginase Pathway) 1,51E00 2,5E-01 ALDH4A1 
Ceramide Biosynthesis 1,34E00 1,67E-01 KDSR 
Citrulline-Nitric Oxide Cycle 1,42E00 2E-01 ASL 
NAD Biosynthesis from 2-amino-3-carboxymuconate Semialdehyde 1,34E00 1,67E-01 QPRT 
PPAR Signaling 1,48E00 3E-02 HSP90B1,NFKBIA,HSP90AB1 
PPARα/RXRα Activation 1,41E00 2,31E-02 ADCY9,HSP90B1,NFKBIA,HSP90AB1 
Proline Degradation 1,81E00 5E-01 ALDH4A1 
S-methyl-5-thio-α-D-ribose 1-phosphate Degradation 1,81E00 5E-01 APIP 
IL-2/RAPA 
ONLY 
Metabolism 
1D-myo-inositol Hexakisphosphate Biosynthesis V (from Ins(1,3,4)P3) 1,47E00 3,33E-01 IPMK 
Acetone Degradation I (to Methylglyoxal) 1,46E00 7,69E-02 CYP2A13/CYP2A6,CYP51A1 
Epoxysqualene Biosynthesis 1,65E00 5E-01 SQLE 
Fatty Acid β-oxidation I 1,37E00 6,9E-02 HADHB,SLC27A2 
Isoleucine Degradation I 1,97E00 1,43E-01 HADHB,ACADSB 
L-serine Degradation 1,47E00 3,33E-01 SRR 
Stearate Biosynthesis I (Animals) 2,25E00 9,38E-02 SLC27A2,DBT,ELOVL1 
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via Mevalonate) 1,86E00 1,25E-01 FDPS,HADHB 
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Tryptophan Degradation III (Eukaryotic) 1,76E00 1,11E-01 HADHB,HAAO 
SHARED IL-2 
AND 
IL-2/RAPA 
Immune 
response 
Antigen Presentation Pathway 6,78E00 1,75E-01 PSMB9,HLA-DMA,HLA-B,HLA-DMB,PSMB8,CD74,TAPBP 
CD28 Signaling in T Helper Cells 1,4E00 3,28E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
CTLA4 Signaling in Cytotoxic T Lymphocytes 1,72E00 4,21E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
Calcium-induced T Lymphocyte Apoptosis 3,3E00 8,2E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1,PRKD3 
Dendritic Cell Maturation 1,35E00 2,6E-02 HLA-DMA,HLA-B,HLA-DMB,HLA-DQB1,FCGR3A 
IL-4 Signaling 2,02E00 5,33E-02 HLA-DMA,IL13RA1,HLA-DMB,HLA-DQB1 
Nur77 Signaling in T Lymphocytes 2,58E00 7,02E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
OX40 Signaling Pathway 3,45E00 8,2E-02 CD3G,HLA-DMA,HLA-B,HLA-DMB,HLA-DQB1 
PKCθ Signaling in T Lymphocytes 1,4E00 3,15E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
Role of NFAT in Regulation of the Immune Response 1,92E00 3,23E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1,FCGR3A,GNG10 
T Helper Cell Differentiation 1,39E00 4,35E-02 HLA-DMA,HLA-DMB,HLA-DQB1 
iCOS-iCOSL Signaling in T Helper Cells 1,53E00 3,57E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
Metabolism 
NAD biosynthesis II (from tryptophan) 2,04E00 1,54E-01 HAAO,QPRT 
Triacylglycerol Biosynthesis 3,3E00 1,21E-01 PPAPDC1B,AGPAT2,DBT,ELOVL1 
Valine Degradation I 2,99E00 1,67E-01 HADHB,ACADSB,DBT 
SHARED 
RAPA AND  
IL-2/RAPA 
Metabolism 
Branched-chain α-keto acid Dehydrogenase Complex 1,35E00 2,5E-01 DBT 
Cholesterol Biosynthesis I 3,42E00 2,31E-01 SQLE,NSDHL,CYP51A1 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 3,42E00 2,31E-01 SQLE,NSDHL,CYP51A1 
Cholesterol Biosynthesis III (via Desmosterol) 3,42E00 2,31E-01 SQLE,NSDHL,CYP51A1 
Geranylgeranyldiphosphate Biosynthesis 1,35E00 2,5E-01 FDPS 
Superpathway of Cholesterol Biosynthesis 4,93E00 1,85E-01 FDPS,SQLE,HADHB,NSDHL,CYP51A1 
Trans, trans-farnesyl Diphosphate Biosynthesis 1,35E00 2,5E-01 FDPS 
Triacylglycerol Biosynthesis 3,3E00 1,21E-01 PPAPDC1B,AGPAT2,DBT,ELOVL1 
Zymosterol Biosynthesis 2,73E00 3,33E-01 NSDHL,CYP51A1 
 
Supplementary Table 1. RAPA alone or combined with IL-2 impacts on liver glucose metabolism: pathway analysis. The table shows the top canonical 
pathways, identified from the Ingenuity canonical pathways library that were most significant to the data sets filtered at 1.2-fold change (see figure 6). Relevant 
pathways were obtained according to the following 2 criteria: 1) Fischer’s exact test was used to calculate a p-value determining the probability that the 
association between the genes in the dataset and the canonical pathway is explained by chance alone (“Log(Pvalue)”); and 2) A ratio of the number of genes 
from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway is displayed (“Ratio”). “Molecules” show the 
genes from the data set included in the corresponding canonical pathway. Pathways were hand-cured and classified as immune (immune response) or metabolic 
(metabolism) pathways. Data are from one experiment with 3 biological replicates for each condition. 
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Supplementary Table 2. Outcome and mechanisms for all the different IL-2- and RAPA-based treatments attempted in the context of T1D prevention 
or reversal in the NOD mouse and humans. 
Treatment/
Condition 
T1D prevention in NOD 
mice 
T1D reversal in 
NOD mice 
T1D 
prevention 
in human 
T1D reversal in 
human 
High-dose 
IL-2 alone 
Precipitates T1D, due to a 
shift from immune 
tolerance to destructive 
autoimmunity.  
ND ND ND 
Low-dose 
IL-2 alone 
Prevents T1D in part by 
specifically boosting 
pancreatic Treg cells (ref 8 
and 13).  
Reverts 
hyperglycemia, 
in part by 
specifically 
boosting 
pancreatic Treg 
cells (ref 9) 
ND 
Completed. 
Awaiting results 
(NCT01353833*) 
RAPA 
alone 
Prevents T1D (ref 13,a,b)  
No efficacy (ref 
14 and b) 
ND 
No negative effect 
(ref 11) 
low-dose 
IL-2 + 
RAPA 
Prevents T1D (ref 13) 
No efficacy. 
RAPA 
counteracts IL-2 
benefic effects 
on Tregs but not 
on NK cells. 
Transient β-cell dysfunction. 
Increase in Tregs, eosinophils and 
NK cells 
(NCT00525889*) 
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Induces glucose 
intolerance. 
ND: not done 
* ClinicalTrials.gov Identifier 
a- Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Clin 
Exp Immunol. 1992 Aug;89(2):174-8. 
b- Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese 
diabetic mice. Shapiro AM, Suarez-Pinzon WL, Power R, Rabinovitch A. Diabetologia. 2002 Feb;45(2):224-30. 
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Supplementary Table 1. RAPA alone or combined with IL-2 impacts on liver glucose metabolism: pathway analysis. The table shows the 
top canonical pathways, identified from the Ingenuity canonical pathways library that were most significant to the data sets filtered at 1.2-fold 
change (see figure 6). Relevant pathways were obtained according to the following 2 criteria: 1) Fischer’s exact test was used to calculate a p-
value determining the probability that the association between the genes in the dataset and the canonical pathway is explained by chance 
alone (“Log(Pvalue)”); and 2) A ratio of the number of genes from the data set that map to the pathway divided by the total number of genes 
that map to the canonical pathway is displayed (“Ratio”). “Molecules” show the genes from the data set included in the corresponding 
canonical pathway. Pathways were hand-cured and classified as immune (immune response) or metabolic (metabolism) pathways. Data are 
from one experiment with 3 biological replicates for each condition. 
 
 
 
 Ingenuity Canonical Pathways  -log(p-value) Ratio Molecules 
IL-2 ONLY 
Immune 
response 
Communication between Innate and Adaptive Immune Cells 3,26E00 7,53E-02 TLR2,IL1RN,TLR6,HLA-B,HLA-DRB1,CD86,HLA-F 
Complement System 1,75E00 9,09E-02 C8B,C1QA,C6 
IL-10 Signaling 1,52E00 5,56E-02 CCR5,BLVRA,IL1RN,CHUK 
IL-8 Signaling 2,33E00 4,69E-02 
PLD4,VEGFA,RAC2,ARRB2,RHOG,CHUK,IQGAP1,FN
BP1,EGFR 
Interferon Signaling 2,57E00 1,18E-01 OAS1,IFITM1,PSMB8,STAT1 
Lipid Antigen Presentation by CD1 1,37E00 9,09E-02 CALR,PDIA3 
NF-κB Signaling 1,63E00 4,12E-02 SIGIRR,TLR2,TGFBR2,IL1RN,TLR6,CHUK,EGFR 
Toll-like Receptor Signaling 2,59E00 8,77E-02 SIGIRR,TLR2,PPARA,TLR6,CHUK 
Metabolis
m 
Lipoate Biosynthesis and Incorporation II 1,46E00 5E-01 LIAS 
PXR/RXR Activation 1,63E00 6,25E-02 PPARA,SCD,ALDH1A1,NR1I2 
Sorbitol Degradation I 1,76E00 1E00 SORD 
Sucrose Degradation V (Mammalian) 2,23E00 2,86E-01 ALDOB,GALM 
Superpathway of Citrulline Metabolism 1,62E00 1,43E-01 ASL,ARG1 
RAPA 
ONLY 
Metabolis
m 
PI3K/AKT Signaling 1,83E00 2,96E-02 HSP90B1,NFKBIA,HSP90AB1,EIF4EBP1 
4-hydroxyproline Degradation I 1,81E00 5E-01 ALDH4A1 
Acetyl-CoA Biosynthesis I (Pyruvate Dehydrogenase Complex) 1,34E00 1,67E-01 DBT 
Arginine Degradation I (Arginase Pathway) 1,51E00 2,5E-01 ALDH4A1 
Ceramide Biosynthesis 1,34E00 1,67E-01 KDSR 
Citrulline-Nitric Oxide Cycle 1,42E00 2E-01 ASL 
NAD Biosynthesis from 2-amino-3-carboxymuconate Semialdehyde 1,34E00 1,67E-01 QPRT 
PPAR Signaling 1,48E00 3E-02 HSP90B1,NFKBIA,HSP90AB1 
PPARα/RXRα Activation 1,41E00 2,31E-02 ADCY9,HSP90B1,NFKBIA,HSP90AB1 
Proline Degradation 1,81E00 5E-01 ALDH4A1 
S-methyl-5-thio-α-D-ribose 1-phosphate Degradation 1,81E00 5E-01 APIP 
IL-2/RAPA Metabolis 1D-myo-inositol Hexakisphosphate Biosynthesis V (from 1,47E00 3,33E-01 IPMK 
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ONLY m Ins(1,3,4)P3) 
Acetone Degradation I (to Methylglyoxal) 1,46E00 7,69E-02 CYP2A13/CYP2A6,CYP51A1 
Epoxysqualene Biosynthesis 1,65E00 5E-01 SQLE 
Fatty Acid β-oxidation I 1,37E00 6,9E-02 HADHB,SLC27A2 
Isoleucine Degradation I 1,97E00 1,43E-01 HADHB,ACADSB 
L-serine Degradation 1,47E00 3,33E-01 SRR 
Stearate Biosynthesis I (Animals) 2,25E00 9,38E-02 SLC27A2,DBT,ELOVL1 
Superpathway of Geranylgeranyldiphosphate Biosynthesis I (via 
Mevalonate) 
1,86E00 1,25E-01 FDPS,HADHB 
Tryptophan Degradation III (Eukaryotic) 1,76E00 1,11E-01 HADHB,HAAO 
SHARED 
IL-2 AND 
IL-2/RAPA 
Immune 
response 
Antigen Presentation Pathway 6,78E00 1,75E-01 
PSMB9,HLA-DMA,HLA-B,HLA-
DMB,PSMB8,CD74,TAPBP 
CD28 Signaling in T Helper Cells 1,4E00 3,28E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
CTLA4 Signaling in Cytotoxic T Lymphocytes 1,72E00 4,21E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
Calcium-induced T Lymphocyte Apoptosis 3,3E00 8,2E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1,PRKD3 
Dendritic Cell Maturation 1,35E00 2,6E-02 HLA-DMA,HLA-B,HLA-DMB,HLA-DQB1,FCGR3A 
IL-4 Signaling 2,02E00 5,33E-02 HLA-DMA,IL13RA1,HLA-DMB,HLA-DQB1 
Nur77 Signaling in T Lymphocytes 2,58E00 7,02E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
OX40 Signaling Pathway 3,45E00 8,2E-02 CD3G,HLA-DMA,HLA-B,HLA-DMB,HLA-DQB1 
PKCθ Signaling in T Lymphocytes 1,4E00 3,15E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
Role of NFAT in Regulation of the Immune Response 1,92E00 3,23E-02 
CD3G,HLA-DMA,HLA-DMB,HLA-
DQB1,FCGR3A,GNG10 
T Helper Cell Differentiation 1,39E00 4,35E-02 HLA-DMA,HLA-DMB,HLA-DQB1 
iCOS-iCOSL Signaling in T Helper Cells 1,53E00 3,57E-02 CD3G,HLA-DMA,HLA-DMB,HLA-DQB1 
Metabolis
m 
NAD biosynthesis II (from tryptophan) 2,04E00 1,54E-01 HAAO,QPRT 
Triacylglycerol Biosynthesis 3,3E00 1,21E-01 PPAPDC1B,AGPAT2,DBT,ELOVL1 
Valine Degradation I 2,99E00 1,67E-01 HADHB,ACADSB,DBT 
SHARED 
RAPA AND  
IL-2/RAPA 
Metabolis
m 
Branched-chain α-keto acid Dehydrogenase Complex 1,35E00 2,5E-01 DBT 
Cholesterol Biosynthesis I 3,42E00 2,31E-01 SQLE,NSDHL,CYP51A1 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 3,42E00 2,31E-01 SQLE,NSDHL,CYP51A1 
Cholesterol Biosynthesis III (via Desmosterol) 3,42E00 2,31E-01 SQLE,NSDHL,CYP51A1 
Geranylgeranyldiphosphate Biosynthesis 1,35E00 2,5E-01 FDPS 
Superpathway of Cholesterol Biosynthesis 4,93E00 1,85E-01 FDPS,SQLE,HADHB,NSDHL,CYP51A1 
Trans, trans-farnesyl Diphosphate Biosynthesis 1,35E00 2,5E-01 FDPS 
Triacylglycerol Biosynthesis 3,3E00 1,21E-01 PPAPDC1B,AGPAT2,DBT,ELOVL1 
Zymosterol Biosynthesis 2,73E00 3,33E-01 NSDHL,CYP51A1 
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Supplementary Table 2. Outcome and mechanisms for all the different IL-2- and RAPA-based 
treatments attempted in the context of T1D prevention or reversal in the NOD mouse and humans. 
 
Treatment/
Condition 
T1D prevention in NOD 
mice 
T1D reversal in 
NOD mice 
T1D 
prevention 
in human 
T1D reversal in 
human 
High-dose 
IL-2 alone 
Precipitates T1D, due to a 
shift from immune 
tolerance to destructive 
autoimmunity.  
ND ND ND 
Low-dose 
IL-2 alone 
Prevents T1D in part by 
specifically boosting 
pancreatic Treg cells (ref 8 
and 13).  
Reverts 
hyperglycemia, 
in part by 
specifically 
boosting 
pancreatic Treg 
cells (ref 9) 
ND 
Completed. 
Awaiting results 
(NCT01353833*) 
RAPA 
alone Prevents T1D (ref 13,a,b)  
No efficacy (ref 
14 and b) ND 
No negative effect 
(ref 11) 
low-dose 
IL-2 + 
RAPA 
Prevents T1D (ref 13) 
No efficacy. 
RAPA 
counteracts IL-2 
benefic effects 
on Tregs but not 
on NK cells. 
Induces glucose 
intolerance. 
Transient β-cell dysfunction. 
Increase in Tregs, eosinophils and 
NK cells 
(NCT00525889*) 
ND: not done 
* ClinicalTrials.gov Identifier 
a- Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Baeder 
WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Clin Exp Immunol. 1992 Aug;89(2):174-8. 
b- Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous 
and recurrent autoimmune diabetes in non-obese diabetic mice. Shapiro AM, Suarez-Pinzon WL, Power 
R, Rabinovitch A. Diabetologia. 2002 Feb;45(2):224-30. 
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Supplementary Figure 1. RAPA alone or combined with IL-2 impacts on liver glucose metabolism: 
microarray analysis. Heat maps show the genes from the comparison of IL-2 vs PBS, IL-2/RAPA vs 
PBS and RAPA vs PBS lists, filtered at 1.5-fold change as depicted in the Venn diagram. The intensity 
of green and red colors indicates the degree of down or up-regulation, respectively. 
 
 
